智能磁性药物输送系统,用于针对性,细胞内输送基抗瘤药物和基抗瘤药
Ludmila Motelica1,2,3, Bogdan Stefan Vasile1,2,3, Denisa Ficai1,3,4
1National Centre for Micro and Nanomaterials & National Centre for Food Safety, Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology Politehnica Bucharest, Spl. Independentei 313, 060042 Bucharest, Romania.
Materials (Basel, Switzerland)
|March 14, 2026
概括
功能化磁纳米粒子 (MNP) 与谷氨酸和PEG涂层增强癌症药物输送. 这些向的MNP改善细胞吸收,并可以通过铁亡诱导癌细胞死亡.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 用Fe3O4涂层的磁纳米粒子 (MNP) 对向癌症治疗具有前景.
- 可以将MNP内化到瘤细胞中,以局部释放抗瘤剂.
- 与健康细胞相比,谷氨酸增强了MNP在瘤细胞中的内化作用.
研究的目的:
- 用谷氨酸使MNP功能化,用聚乙烯糖醇 (PEG) 稳定,以改善癌症药物输送.
- 评估这些功能化的MNP作为抗瘤药物的输送系统的有效性.
- 研究MNP在癌细胞中诱导铁亡的潜力.
主要方法:
- 用谷氨酸对Fe3O4 MNPs的功能化.
- 使用PEG涂层稳定功能化的MNP.
- 在MNP上加载抗瘤药物 ( irinotcan, carboplatin, cisplatin)
- 评估MNP内部化效率进入瘤细胞.
- 评估MNP稳定性和细胞局部 (线粒体,脂质囊泡).
主要成果:
- 谷氨酸功能化和PEG稳定显著改善了MNP在瘤细胞中的内部化.
- 开发的MNP系统表现出稳定性,允许透到线粒体.
- 含有西斯的MNP在0.1mg/ml的度下显示出最有效的结果.
- 该系统有可能诱导铁,一种依赖铁的细胞死亡过程.
结论:
- 功能化和PEG涂层的MNP代表了针对癌症药物的有效策略.
- 这种MNP系统通过将药物集中在瘤部位来增强药物的疗效.
- 这些MNP显示出个性化癌症治疗的潜力,包括诱导铁亡.
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
01:27Drug Delivery Systems: Different Types
166
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
166
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
01:23Modified-Release Drug Delivery Systems: Classification
167
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
167
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
73
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
73
01:26Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135